Results 261 to 270 of about 17,488 (290)
Some of the next articles are maybe not open access.
2015
Biopharmaceutics is the field that investigates and describes everything that happens with a medicinal product and the active substance between the moment of administration, the moment it exerts its action and the moment it is eliminated from the body. Biopharmaceutics connects the physico-chemical properties of an active substance and its dosage form ...
Frijlink, Henderik W. +2 more
openaire +1 more source
Biopharmaceutics is the field that investigates and describes everything that happens with a medicinal product and the active substance between the moment of administration, the moment it exerts its action and the moment it is eliminated from the body. Biopharmaceutics connects the physico-chemical properties of an active substance and its dosage form ...
Frijlink, Henderik W. +2 more
openaire +1 more source
Veterinary-based biopharmaceuticals
Trends in Biotechnology, 2012The veterinary vaccine market is forecast to grow consistently over the next several years [12xVeterinary Vaccines Market to 2017. GBI Research. See all References[12]. Moreover, the vaccine market for companion animals is growing more rapidly than any other animal health sector [13xSee all References[13].
Michael P, Ryan, Gary, Walsh
openaire +2 more sources
Biopharmaceutical benchmarks 2014
Nature Biotechnology, 2014Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a dramatic slowdown in recent years.
openaire +2 more sources
Theranostic of biopharmaceuticals
Pharmacology & Therapeutics, 2017Monoclonal antibodies (mAbs) and fusion proteins with an Fc portion of immunoglobulin G (IgG) are emblematic of the remarkable expansion of biopharmaceuticals. Despite their biological origin, these products display an interindividual variability in their efficacy and/or side effects, which must be taken into consideration.
Benjamin, Chaigne, Hervé, Watier
openaire +2 more sources
Biopharmaceutical benchmarks 2010
Nature Biotechnology, 2010Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic approval landscape.
openaire +2 more sources
European Biopharmaceutical Culture
Nature Biotechnology, 1990Article synthese abordant le cote economique de l'utilisation du genie genetique pour la production de molecules recombinantes, par les industries biopharmaceutiques ...
openaire +2 more sources
Biopharmaceutical benchmarks 2006
Nature Biotechnology, 2006The rate of biopharmaceutical approvals has leveled off, but some milestones bode well for the future.
openaire +2 more sources